- About Us
- Drug Discovery
- Regenerative Medicine
- News & Events
- Contact Us
News & Events > Press Releases
"Maxim Group" Published Additional Industry Review Marking Kadimastem as a Noteworthy CompanyMar. 9, 2016
One year after noting Kadimastem as one of the promising companies operating in the ALS field, Jason Kolbert, Head of Healthcare Research at the American investment bank Maxim Group, published another review noting the company.
In his review, Jason Kolbert, a leading US analyst in the biotechnology field in general and cell therapy in particular, marks Kadimastem as a noteworthy company. The report reviews the company's technology, its successful trials so far and its two primary indications: diabetes and ALS.
The Kadimastem review - http://www.kadimastem.com/files/files/The-Renaissance-of-Medicine-in-Israel.pdf
Press Releases Archive